Drug × Cancer matrix

Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Relationship
Show
Clear
Showing 200 of 837 drug-target rows in SSL view, for TSG = TSC1.
Drug TSG SLP (drug target) GBM LUAD SCLC LUSC OAC OSCC PDAC #
sunitinib TSC1 KIT 6
tucatinib TSC1 ERBB2 6
afatinib TSC1 ERBB2 3
bevacizumab TSC1 VEGFA 3
dec-205/ny-eso-1 fusion protein cdx-1401, laboratory biomarker analysis, pharmacological study, sirolimus TSC1 MTOR 3
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab TSC1 VEGFA 3
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab TSC1 ABL1 3
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab TSC1 KIT 3
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) TSC1 ABL1 3
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) TSC1 KIT 3
abemaciclib TSC1 CDK6 6
avapritinib TSC1 KIT 6
lapatinib TSC1 ERBB2 6
pazopanib TSC1 KIT 6
sacituzumab govitecan TSC1 TOP1 6
topotecan TSC1 TOP1 6
trastuzumab emtansine TSC1 ERBB2 6
trastuzumab deruxtecan TSC1 TOP1 5
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine TSC1 VEGFA 2
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine TSC1 TYMS 2
ab598, zimberelimab, fluorouracil, leucovorin, oxaliplatin TSC1 TYMS 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib TSC1 WEE1 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib TSC1 CDK6 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib TSC1 ABL1 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib TSC1 BTK 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib TSC1 MAP2K1 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib TSC1 ERBB2 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib TSC1 SMO 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib TSC1 SRC 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib TSC1 KIT 2
adavosertib, radiation therapy TSC1 WEE1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel TSC1 TYMS 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel TSC1 IGF1R 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel TSC1 ABL1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel TSC1 MAP2K1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel TSC1 DHFR 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel TSC1 ERBB2 2
alvocidib, paclitaxel TSC1 CDK6 2
alvocidib, paclitaxel TSC1 CDK9 2
apatinib, irinotecan TSC1 TOP1 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine TSC1 TYMS 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine TSC1 TOP1 2
avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 TSC1 TYMS 2
avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 TSC1 DHFR 2
bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil, therapeutic conventional surgery, laboratory biomarker analysis TSC1 VEGFA 2
bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil, therapeutic conventional surgery, laboratory biomarker analysis TSC1 TYMS 2
biospecimen collection, computed tomography, pemetrexed TSC1 TYMS 2
biospecimen collection, computed tomography, pemetrexed TSC1 DHFR 2
bryostatin 1, paclitaxel TSC1 CASP8 2
capecitabine, carboplatin, epirubicin hydrochloride TSC1 TYMS 2
capecitabine, cisplatin TSC1 TYMS 2
capecitabine, oxaliplatin, gene expression analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, quality-of-life assessment, radiation therapy TSC1 TYMS 2
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy TSC1 TYMS 2
cetuximab, cisplatin, fluorouracil, conventional surgery TSC1 TYMS 2
cetuximab, cisplatin, irinotecan, radiation therapy, surgery TSC1 TOP1 2
cft1946, trametinib, cetuximab TSC1 MAP2K1 2
chemotherapy, cisplatin, fluorouracil, low-let electron therapy, low-let photon therapy TSC1 TYMS 2
cisplatin, fluorouracil, conventional surgery, neoadjuvant therapy, radiation therapy TSC1 TYMS 2
cisplatin, fluorouracil, iressa, conventional surgery, radiation therapy TSC1 TYMS 2
cisplatin, fluorouracil, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy TSC1 TYMS 2
cisplatin, fluorouracil, paclitaxel, surgical procedure, radiation therapy TSC1 TYMS 2
cisplatin, fluorouracil, surgical procedure, radiation therapy TSC1 TYMS 2
cisplatin, pemetrexed, gemcitabine, carboplatin, certolizumab, nivolumab TSC1 TYMS 2
cisplatin, pemetrexed, gemcitabine, carboplatin, certolizumab, nivolumab TSC1 DHFR 2
cixutumumab, laboratory biomarker analysis, paclitaxel, pharmacological study TSC1 IGF1R 2
cobimetinib, mehd7945a TSC1 MAP2K1 2
durvalumab, tremelimumab, oxaliplatin, capecitabine, radiotherapy, paclitaxel, carboplatin, 5-fluorouracil (5-fu), leucovorin, docetaxel TSC1 TYMS 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab TSC1 CDK6 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab TSC1 ERBB2 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib TSC1 ERBB2 2
erlotinib hydrochloride, oxaliplatin, fluorouracil, radiation therapy, conventional surgery, immunohistochemistry staining method, positron emission tomography, computed tomography, laboratory biomarker analysis, gene expression analysis, fludeoxyglucose f 18 TSC1 TYMS 2
filgrastim, cisplatin, fluorouracil, paclitaxel, radiation therapy TSC1 TYMS 2
filgrastim, pegfilgrastim, cisplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy TSC1 TYMS 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study TSC1 TYMS 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study TSC1 HDAC8 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study TSC1 HDAC6 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study TSC1 HDAC2 2
fluorouracil, oxaliplatin, conventional surgery, radiation therapy TSC1 TYMS 2
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan TSC1 TOP1 2
gemcitabine TSC1 TYMS 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a TSC1 KIT 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib TSC1 TYMS 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib TSC1 DHFR 2
irinotecan, capecitabine TSC1 TYMS 2
irinotecan, capecitabine TSC1 TOP1 2
irinotecan, docetaxel TSC1 TOP1 2
jab-3312, binimetinib, pembrolizumab, sotorasib, osimertinib TSC1 MAP2K1 2
laboratory biomarker analysis, oxaliplatin, pralatrexate TSC1 TYMS 2
laboratory biomarker analysis, oxaliplatin, pralatrexate TSC1 DHFR 2
lenvatinib, pembrolizumab TSC1 KIT 2
lurbinectedin, irinotecan TSC1 TOP1 2
m6620, cisplatin, capecitabine, radiotherapy TSC1 TYMS 2
mirdametinib, bgb-3245 TSC1 MAP2K1 2
mrtx849, pembrolizumab, cetuximab, afatinib TSC1 ERBB2 2
nintedanib TSC1 SRC 2
nintedanib, pembrolizumab TSC1 SRC 2
ociperlimab, tislelizumab, pemetrexed, paclitaxel, nab paclitaxel, carboplatin, cisplatin, etoposide, 5fluorouracil, oxaliplatin, capecitabine TSC1 TYMS 2
ociperlimab, tislelizumab, pemetrexed, paclitaxel, nab paclitaxel, carboplatin, cisplatin, etoposide, 5fluorouracil, oxaliplatin, capecitabine TSC1 DHFR 2
osimertinib, bevacizumab, osimertinib TSC1 VEGFA 2
pd-1 inhibitor, bevacizumab, carboplatin, cisplatin, pemtrexed TSC1 VEGFA 2
pembrolizumab, belzutifan, lenvatinib TSC1 KIT 2
pembrolizumab, guadecitabine, mocetinostat TSC1 HDAC2 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu TSC1 TYMS 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu TSC1 KIT 2
pembrolizumab, paclitaxel, docetaxel, irinotecan TSC1 TOP1 2
pembrolizumab, sonidegib TSC1 SMO 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin TSC1 VEGFA 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin TSC1 TYMS 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin TSC1 KIT 2
pemetrexed, bevacizumab TSC1 VEGFA 2
pemetrexed, bevacizumab TSC1 TYMS 2
pemetrexed, bevacizumab TSC1 DHFR 2
pralatrexate, docetaxel, fludeoxyglucose f 18, positron emission tomography TSC1 TYMS 2
pralatrexate, docetaxel, fludeoxyglucose f 18, positron emission tomography TSC1 DHFR 2
rubitecan TSC1 TOP1 2
sar444881, pembrolizumab, cetuximab, carboplatin, pemetrexed TSC1 TYMS 2
sar444881, pembrolizumab, cetuximab, carboplatin, pemetrexed TSC1 DHFR 2
sorafenib, administered orally, ct/mri TSC1 KIT 2
srf617, gemcitabine, albumin-bound paclitaxel, pembrolizumab TSC1 TYMS 2
temsirolimus TSC1 MTOR 2
tislelizumab, pemetrexed TSC1 TYMS 2
tislelizumab, pemetrexed TSC1 DHFR 2
trastuzumab TSC1 ERBB2 2
trastuzumab, abt-806, bemarituzumab, ramucirumab, nivolumab, standard cytotherapy TSC1 ERBB2 2
tucidinostat (chidamide), pd-1 inhibitor (toripalimab), bevacizumab TSC1 VEGFA 2
whole brain low dose radiotherapy, pemetrexed, sintilimab, chemotherapy TSC1 TYMS 2
whole brain low dose radiotherapy, pemetrexed, sintilimab, chemotherapy TSC1 DHFR 2
binimetinib TSC1 MAP2K1 6
bosutinib TSC1 ABL1 6
bosutinib TSC1 SRC 6
capecitabine TSC1 TYMS 6
everolimus TSC1 MTOR 6
ibrutinib TSC1 BTK 6
palbociclib TSC1 CDK6 6
pemetrexed TSC1 TYMS 6
pemetrexed TSC1 DHFR 6
ponatinib TSC1 ABL1 6
regorafenib TSC1 ABL1 6
regorafenib TSC1 KIT 6
ribociclib TSC1 CDK6 6
romidepsin TSC1 HDAC6 6
romidepsin TSC1 HDAC2 6
selumetinib TSC1 MAP2K1 6
sorafenib TSC1 KIT 6
trilaciclib TSC1 CDK6 6
2b3-101, trastuzumab, 2b3-101 60 mg/m2 every 4 weeks, 2b3-101 50 mg/m2 every 3 weeks TSC1 ERBB2 1
3-dimensional conformal radiation therapy, bevacizumab, cisplatin, fluorouracil, intensity-modulated radiation therapy TSC1 VEGFA 1
3-dimensional conformal radiation therapy, bevacizumab, cisplatin, fluorouracil, intensity-modulated radiation therapy TSC1 TYMS 1
3-dimensional conformal radiation therapy, bevacizumab, intensity-modulated radiation therapy, laboratory biomarker analysis, placebo, quality-of-life assessment, temozolomide TSC1 VEGFA 1
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat TSC1 HDAC8 1
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat TSC1 HDAC6 1
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat TSC1 HDAC2 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat TSC1 HDAC8 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat TSC1 HDAC6 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat TSC1 HDAC2 1
5-fluorouracil (5-fu), leucovorin, oxaliplatin, atezolizumab, cobimetinib, ramucirumab, paclitaxel, pegylated recombinant human hyaluronidase (pegph20), bl-8040, linagliptin, atezolizumab, cobimetinib, cisplatin, tiragolumab, 5-fluorouracil (5-fu) TSC1 MAP2K1 1
5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin TSC1 VEGFA 1
5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin TSC1 TYMS 1
5-fu, leucovorin, docetaxel, oxaliplatin (flot), trastuzumab, post-operative treatment trastuzumab mono therapy TSC1 ERBB2 1
5fu, nab-paclitaxel, bevacizumab, calcium leucovorin, oxaliplatin TSC1 VEGFA 1
abbv-400, budigalimab, fluorouracil, leucovorin, oxaliplatin TSC1 TYMS 1
abemaciclib, abemaciclib TSC1 CDK6 1
abemaciclib, bevacizumab TSC1 VEGFA 1
abemaciclib, bevacizumab TSC1 CDK6 1
abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf TSC1 TOP1 1
abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf TSC1 CDK6 1
abemaciclib, ly3214996 TSC1 CDK6 1
abemaciclib, surgery TSC1 CDK6 1
adavosertib TSC1 WEE1 1
adavosertib, laboratory biomarker analysis, pharmacological study, radiation therapy TSC1 WEE1 1
adavosertib, radiation therapy, temozolomide TSC1 WEE1 1
adebrelimab, apatinib, tegafur TSC1 TYMS 1
adjuvant therapy, temozolomide, valproic acid, radiation therapy TSC1 HDAC2 1
adriamycin, cyclophosphamide, vindesine, valproic acid TSC1 HDAC2 1
aee788, everolimus TSC1 MTOR 1
afatinib, biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging TSC1 ERBB2 1
afatinib, dasatinib, palbociclib, everolimus, olaparib TSC1 CDK6 1
afatinib, dasatinib, palbociclib, everolimus, olaparib TSC1 ABL1 1
afatinib, dasatinib, palbociclib, everolimus, olaparib TSC1 BTK 1
afatinib, dasatinib, palbociclib, everolimus, olaparib TSC1 ERBB2 1
afatinib, dasatinib, palbociclib, everolimus, olaparib TSC1 SRC 1
afatinib, dasatinib, palbociclib, everolimus, olaparib TSC1 KIT 1
afatinib, dasatinib, palbociclib, everolimus, olaparib TSC1 MTOR 1
afatinib, docetaxel, radiation therapy TSC1 ERBB2 1
afatinib, gefitinib TSC1 ERBB2 1
afatinib, irinotecan TSC1 TOP1 1
afatinib, irinotecan TSC1 ERBB2 1
ak104, oxaliplatin, capecitabine TSC1 TYMS 1
aldoxorubicin, topotecan TSC1 TOP1 1
amg 386 placebo, amg 386 10mg/kg, amg 386 3mg/kg, cisplatin, capecitabine, cisplatin, capecitabine, cisplatin, capecitabine TSC1 TYMS 1
amgen 386, bevacizumab TSC1 VEGFA 1
amrubicin, topotecan TSC1 TOP1 1
ang1005, bevacizumab TSC1 VEGFA 1
anti-endoglin chimeric monoclonal antibody trc105, bevacizumab, laboratory biomarker analysis, pharmacological study, quality-of-life assessment TSC1 VEGFA 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib TSC1 CDK6 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib TSC1 SMO 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib TSC1 MTOR 1
asc40 tablets, placebo tablets, bevacizumab TSC1 VEGFA 1
askb589, oxaliplatin, capecitabine, tislelizumab, placebo TSC1 TYMS 1
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan TSC1 TYMS 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable candidates from cansar.ai — these are potential drug-cancer reuse candidates, not evidence of efficacy.